Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Bower

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|June 8, 2020
Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort studyAnna Plym, Anna L V Johansson, Hannah Bower, et al.
Annals of the Rheumatic Diseases|March 13, 2026
Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide studyViking Huss, Hannah Bower, Martin Björklund, et al.
Haematologica|September 25, 2025
Loss of life expectancy in patients with myeloproliferative neoplasms in SwedenYuliya Leontyeva, Anna Ravn Landtblom, Malin Hultcrantz, et al.
Rheumatology (Oxford, England)|December 17, 2021
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in SwedenDaniela Di Giuseppe, Ulf Lindstrom, Hannah Bower, et al.
Leukemia|March 15, 2018
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patientsAnna Ravn Landtblom, Hannah Bower, Therese M-L Andersson, et al.
Breast (Edinburgh, Scotland)|March 25, 2019
Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenariosHannah Bower, Therese M-L Andersson, Elisavet Syriopoulou, et al.
BMC Medical Research Methodology|November 10, 2022
Modelling multiple time-scales with flexible parametric survival modelsNurgul Batyrbekova, Hannah Bower, Paul W Dickman, et al.
RMD Open|December 27, 2023
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in SwedenHannah Bower, Thomas Frisell, Daniela di Giuseppe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 23, 2024
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort StudyAnna Eberhard, Daniela Di Giuseppe, Johan Askling, et al.
Annals of the Rheumatic Diseases|February 14, 2023
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programmeThomas Frisell, Hannah Bower, Matilda Morin, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|June 8, 2020
Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort studyAnna Plym, Anna L V Johansson, Hannah Bower, et al.
Annals of the Rheumatic Diseases|March 13, 2026
Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide studyViking Huss, Hannah Bower, Martin Björklund, et al.
Haematologica|September 25, 2025
Loss of life expectancy in patients with myeloproliferative neoplasms in SwedenYuliya Leontyeva, Anna Ravn Landtblom, Malin Hultcrantz, et al.
Rheumatology (Oxford, England)|December 17, 2021
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in SwedenDaniela Di Giuseppe, Ulf Lindstrom, Hannah Bower, et al.
Leukemia|March 15, 2018
Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patientsAnna Ravn Landtblom, Hannah Bower, Therese M-L Andersson, et al.
Breast (Edinburgh, Scotland)|March 25, 2019
Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenariosHannah Bower, Therese M-L Andersson, Elisavet Syriopoulou, et al.
BMC Medical Research Methodology|November 10, 2022
Modelling multiple time-scales with flexible parametric survival modelsNurgul Batyrbekova, Hannah Bower, Paul W Dickman, et al.
RMD Open|December 27, 2023
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in SwedenHannah Bower, Thomas Frisell, Daniela di Giuseppe, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 23, 2024
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort StudyAnna Eberhard, Daniela Di Giuseppe, Johan Askling, et al.
Annals of the Rheumatic Diseases|February 14, 2023
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programmeThomas Frisell, Hannah Bower, Matilda Morin, et al.
Pageof 4